Morgan Cheatham

Morgan Cheatham is a Vice President with Bessemer Venture Partners where he leads healthcare and life sciences investments from seed to growth stages. He focuses across the value chain spanning software, therapeutics, services, and diagnostics and specializes in applications of computation in biomedicine.

Select investments in his portfolio include Abridge, Hinge Health, Headspace Health, Subtle Medical, Turquoise Health, Productboard, Plenful, Groups, Ansible Health, and FOLX Health. He was awarded Forbes 30U30 for Venture Capital and the National Venture Capital Association Rising Star Award in 2023.

Morgan is pursuing medical training at Brown University with a research focus in bioinformatics. His work investigates questions pertaining to clinical validation, phenotyping, and therapeutic response prediction via large multi-modal model approaches in collaboration with the Shah Lab at Stanford and the Zitnik Lab at Harvard. Morgan is also a member of the NEJM AI editorial team.